RIBOLIFE-B (06938) rose more than 7% during early trading. At the time of writing, the stock was up 6.04%, trading at HK$72.9, with a turnover of HK$11.7261 million. The company announced that its core product, Vortosiran (RBD4059), has successfully submitted a Phase IIb clinical trial application (CTA) to the European Medicines Agency (EMA) for stroke prevention in atrial fibrillation (SPAF) patients. This marks the world’s first small interfering RNA (siRNA) Factor XI (FXI) inhibitor to enter clinical trials for atrial fibrillation (AF), representing a significant milestone in the clinical development of siRNA therapies in the anticoagulation field. RIBOLIFE-B has planned a series of Phase IIb clinical studies covering multiple thrombotic and cardiovascular indications, with the recently submitted trial, coded ORBIT-XI-AF, being one of them. Following the completion of Vortosiran’s Phase IIa trial for coronary artery disease (CAD), this submission further strengthens the product’s position as the fastest-developing FXI-targeting small nucleic acid drug globally.